Keros Therapeutics (KROS) FCF Margin (2019 - 2025)
Keros Therapeutics' (KROS) quarterly FCF Margin came in at 15339.36% in Q4 2025, down 1381744.0% YoY from N/an in Q4 2024, and down 47936.86% on a QoQ basis from 32.07% in Q3 2025.
Keros Therapeutics (KROS) FCF Margin (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 6 years of FCF Margin data on file, last reported at 15339.36% in Q4 2025.
- Quarterly FCF Margin fell 1381744.0% year-over-year to 15339.36% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 43.47% (up 467769.0% YoY) and the FY2025 annual result came in at 43.45%, up 462936.0% from the prior year.
- FCF Margin slipped to 15339.36% in Q4 2025, from 32.07% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 76.03% in Q1 2025 to a low of 431650.0% in Q3 2023.
- A 5-year average of 45518.48% and a median of 4741.12% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2024 — FCF Margin jumped 42368969 bps — and 2025, when it sank 1381744 bps.
- Tracing KROS's FCF Margin over 5 years: stood at 110.19% in 2021, then soared by 92 bps to 8.41% in 2022, then plunged by 216064 bps to 18181.82% in 2023, then surged by 92 bps to 1521.93% in 2024, then tumbled by 908 bps to 15339.36% in 2025.
- The last three FCF Margin figures came in at 15339.36% (Q4 2025), 32.07% (Q3 2025), and 167.01% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 70.82% |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15,339.36% |
| Sep 30, 2025 | 32.07% |
| Jun 30, 2025 | -167.01% |
| Mar 31, 2025 | 76.03% |
| Dec 31, 2024 | -1,521.93% |
| Sep 30, 2024 | -7,960.31% |
| Mar 31, 2024 | -53,963.86% |
| Dec 31, 2023 | -18,181.82% |
| Sep 30, 2023 | -431,650.00% |
| Mar 31, 2022 | -8.41% |
| Dec 31, 2021 | -110.19% |
| Jun 30, 2021 | -17,427.00% |
| Dec 31, 2019 | -220.64% |
| Sep 30, 2019 | -121.48% |
| Jun 30, 2019 | -208.12% |
| Mar 31, 2019 | -100.52% |